New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Amgen, Astrazeneca, Bayer, Blueprint, BMS, Chi-Med, Eisai, Exelixis, Genentech, Genmab, Immunomedics, Innovent, Ipsen, Janssen, Lilly, Macrogenics, Merck, Novartis, Oncternal, Ose, Pieris, Regeneron, Roche, Sanofi, Seattle Genetics, Veru.
New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Agenus, Alkermes, Astrazeneca, Autolus, Ayala, Beigene, Daiichi, Deciphera, Eisai, Essa, Faron, Helsinn, Immunomedics, Immutep, Incyte, IO, Ipsen, Italfarmaco, Menarini, Mirati, Regeneron, Sanofi, Sensei, Spectrum, Sumitomo, Takeda.
New and updated preclinical and clinical data to be presented by biopharma firms at the
European Society for Medical Oncology Virtual Congress 2020, including: ADC, Amunix, Bayer, Blueprint, BMS, Cardiff Oncology, Clovis, Corvus, Cullinan Pearl, Deciphera, Genentech, Genocea, Halozyme, Immunicum, Immunogen, Mersana, Noxxon, Oryzon, Roche, VBI.
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
TORONTO – Several U.S. and Canadian patients have recently undergone successful mitral valve surgery featuring a platform designed by Toronto-based Baylis Medical Inc. to provide more precise access to the wall separating the left and right sides of the heart. Robert Harrison, Baylis's director of research and development for cardiology, said in addition to locating the precise puncture point for mitral valve reconstruction, the Versacross transseptal solution has reduced the number of devices exchanged during the procedure to an all-in-one platform.
BARCELONA, Spain – Sunday's Presidential Symposium at the 2019 Congress of the European Society of Medical Oncology was devoted to breast cancer studies, and two of those studies – MONARCH-2 and MONALEESA-3 – reported an overall survival (OS) benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive (HR+) breast cancer in several different settings.
BARCELONA, Spain – At the 2019 Conference of the European Society of Medical Oncology (ESMO), results from the ClarIDHy and FIGHT-202 trials, both testing drugs for the treatment of cholangiocarcinoma, illustrated how molecular medicine can bring new treatments to rare tumors.
BARCELONA, Spain – This year's theme at the European Society for Medical Oncology's (ESMO) 2019 annual meeting is "translating science into better patient care."